Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
By M. Sulkowski, David F. Gardiner, M. Rodríguez-Torres, K. R. Reddy, Tarek Hassanein, Ira M. Jacobson, E. Lawitz, Anna S. Lok, F. Hinestrosa, P. Thuluvath and 14 more. New England Journal of Medicine, 2014
1,263 citations recorded by the source corpus.
Subfields: Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/1871de70b64a9c39179f80dfa6745f26e0160a2f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Public Health, Environmental and Occupational Health
Citations in the corpus
- EASL Clinical Practice Guidelines: Liver transplantation. (2016, background): “The combination of sofosbuvir, daclatasvir and RBV has also shown a high efficacy in phase II studies including a small number of patients with compensated cirrhosis, and can be used in all genotypes [39].”
- EASL Recommendations on Treatment of Hepatitis C 2015. (2015, background): “With 12 weeks of therapy, SVR was achieved in 98% (40/41) of treatment-naïve patients without ribavirin (the remaining patient was lost to follow-up) [14].”
- All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study (2015, methodology): “These results are generally consistent with those from a phase II study demonstrating the efficacy and tolerability of DCV plus SOF, with or without RBV, in patients with genotype 3 infection.(17) Overall, findings from the present study show that in genotype 3– infected patients without cirrhosis, ”
- Global Distribution and Prevalence of Hepatitis C Virus Genotypes (2014, background): “It is important to note that the most prevalent genotype in developed economies (genotype 1) is also the most prevalent globally and should be well served by interferon-free regimens of secondgeneration DAA therapies with viral eradication rates of >90%.(13,32) Genotype 3, however, which accounts fo”
- EASL Recommendations on Treatment of Hepatitis C 2016. (2017, background): “In a Phase IIb trial with this combination 24 weeks [29], the SVR rate was 89% (16/18) in treatment-naïve non-cirrhotic patients infected with HCV genotype 3.”
- EASL Recommendations on Treatment of Hepatitis C 2018. (2018, background): “In a Phase IIb trial with this combination 24 weeks [29], the SVR rate was 89% (16/18) in treatment-naïve non-cirrhotic patients infected with HCV genotype 3.”